Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Invest New Drugs. 2018 Jul 28;37(1):147–158. doi: 10.1007/s10637-018-0646-1

Table 4.

U3–1565 Plasma PK Parameters in Part 2, Cycle 1 and Cycle 3

Cycle 1 Cycle 3
n 21 21
Cmax (μg/mL) 486 (141) 1121 (328)
tmax (h) 3.93 (1.00–7.00) 6.72 (0.97–74.4)
AUCtau (mg h/mL)# 44.7 (11.8) 147 (38.3)
Half-life (h)#* 163 (60.8) 469 (290)
#

PK parameters are based on time points collected over 1 week.

*

Half-life was only evaluable for 15 subjects in Cycle 1, and for 10 subjects in Cycle 3. Mean (standard deviation) is reported above. For tmax, median (min, max) is reported. n = number of subjects